Mepolizumab use in cystic fibrosis-associated allergic bronchopulmonary aspergillosis

Maeve Boyle, Siobhain Mulrennan, Sue Morey, Sona Vekaria, Natalia Popowicz, Anna Tai

Research output: Contribution to journalArticlepeer-review

11 Citations (Web of Science)

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) is common in cystic fibrosis (CF). Treatment is challenging and the relapse rate is high. Standard therapy is oral steroids and antifungals. However, long-term systemic steroid often results in adverse effects and drug interactions between azoles and CFTR modulators are a potential concern. Mepolizumab, an anti-interleukin (IL)-5 monoclonal antibody, can benefit patients with severe eosinophilic asthma and there are reports of mepolizumab use in ABPA but not in ABPA complicating CF. We present the case of an adult with CF who had recurrent ABPA and intolerable treatment side effects with steroid, azole, and omalizumab. Mepolizumab was well tolerated and led to significantly improved clinical stability and symptomatic improvement. To our knowledge, this is the first report of successful mepolizumab treatment for ABPA in CF. Mepolizumab may be an important adjunctive treatment for difficult to control ABPA in CF.

Original languageEnglish
Article numbere00696
JournalRespirology Case Reports
Volume9
Issue number1
DOIs
Publication statusPublished - Jan 2021

Fingerprint

Dive into the research topics of 'Mepolizumab use in cystic fibrosis-associated allergic bronchopulmonary aspergillosis'. Together they form a unique fingerprint.

Cite this